GlobeNewsWire
15 Jun 2026, 17:36 UTC · 2h ago
Nordicus Partners Corporation Corporate Update
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
GlobeNewsWire
15 Jun 2026, 17:36 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Orocidin's QR-01 candidate demonstrated efficacy in two animal studies and is expected to begin Phase IIa human clinical trials in the first half of 2027. — Successful animal data and a clear timeline for human trials represent a major de-risking step for a lead pipeline candidate.
+0.60Nordicus Partners is currently in the process of applying to uplist its common shares from the OTCQB to a major stock exchange. — Uplisting typically increases liquidity and institutional visibility, which generally supports a higher valuation.
+0.40Bio-Convert's QR-02 candidate received a toxicity waiver from the Danish Medicine Agency and is expected to enter Phase IIa trials in early 2027. — Regulatory waivers and a path to clinical trials are positive developments, though the timeline is further out than current milestones.
+0.30Continue reading
6 related stories
Search tags
NoviThera's QR-04 treatment for psoriasis has demonstrated biological proof of concept in a recent mouse study. — Proof of concept in mice is an early-stage win, but far from clinical validation or commercialization.
+0.20Which stocks this story touches
The company reported successful animal studies for QR-01, a toxicity waiver for QR-02, and biological proof of concept for QR-04, alongside an ongoing Nasdaq uplisting process.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
1d ago
